Sen. Sheldon Whitehouse Sells Off Shares of Danaher Corporation (NYSE:DHR)

Key Points

• Senator Sheldon Whitehouse disclosed the sale of shares in Danaher Corporation (NYSE:DHR), selling between $1,001 and $15,000 on August 28th.
• Danaher reported a better-than-expected earnings per share of $1.80 for the last quarter, surpassing analysts' estimates, and has set its FY 2025 guidance between $7.700-$7.800 EPS.
• Analyst ratings for Danaher include several "buy" ratings with a consensus target price of $246.35, indicating strong investor confidence.

Senator Sheldon Whitehouse (D-Rhode Island) recently sold shares of Danaher Corporation NYSE: DHR. In a filing disclosed on September 03rd, the Senator disclosed that they had sold between $1,001 and $15,000 in Danaher stock on August 28th.

Senator Sheldon Whitehouse also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Kenvue NYSE: KVUE on 8/28/2025.
• Sold $15,001 - $50,000 in shares of UnitedHealth Group NYSE: UNH on 8/28/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 8/28/2025.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 7/7/2025.
• Sold $15,001 - $50,000 in shares of Analog Devices NASDAQ: ADI on 7/3/2025.

Danaher Price Performance

DHR stock traded up $1.29 during midday trading on Friday, reaching $200.32. 2,837,584 shares of the stock were exchanged, compared to its average volume of 2,859,442. The stock has a market capitalization of $143.44 billion, a PE ratio of 42.62, a P/E/G ratio of 2.79 and a beta of 0.75. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The company has a fifty day moving average price of $201.93 and a 200 day moving average price of $199.37.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Institutional Trading of Danaher

Institutional investors and hedge funds have recently modified their holdings of the stock. MGO One Seven LLC increased its position in shares of Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after purchasing an additional 20,813 shares during the last quarter. Asahi Life Asset Management CO. LTD. purchased a new stake in shares of Danaher during the 1st quarter valued at $539,000. Horizon Financial Services LLC increased its position in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after purchasing an additional 8,160 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc grew its holdings in Danaher by 6.1% during the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 34,763 shares of the conglomerate's stock valued at $7,126,000 after purchasing an additional 2,009 shares during the period. Finally, EFG Asset Management Americas Corp. grew its holdings in Danaher by 13.1% during the first quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate's stock valued at $7,396,000 after purchasing an additional 4,191 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research report on Tuesday. UBS Group reduced their price target on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Barclays reiterated an "overweight" rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft dropped their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Finally, Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $246.35.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.10% of the company's stock.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031. Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.